牛牛AI助理已提取核心訊息
RedHill Biopharma Ltd., a biopharmaceutical company, has been the subject of a recent Schedule 13G amendment filing with the Securities and Exchange Commission (SEC) on December 31, 2023. The filing was made by Empery Asset Management, LP, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, along with its managing members Ryan M. Lane and Martin D. Hoe. The filing indicates that Empery Asset Management, LP holds 647,824 American Depository Shares (ADSs), equivalent to 259,129,600 Ordinary Shares of RedHill Biopharma, issuable upon the exercise of warrants. This represents approximately 3.19% of the company's class of securities. The warrants are subject to a 4.99% ownership blocker, which prevents the full exercise of the warrants if it would result in ownership exceeding this threshold. As a result, the actual number of Ordinary Shares beneficially owned by the reporting persons is less than the number reported. The filing also includes a certification that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
RedHill Biopharma Ltd., a biopharmaceutical company, has been the subject of a recent Schedule 13G amendment filing with the Securities and Exchange Commission (SEC) on December 31, 2023. The filing was made by Empery Asset Management, LP, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, along with its managing members Ryan M. Lane and Martin D. Hoe. The filing indicates that Empery Asset Management, LP holds 647,824 American Depository Shares (ADSs), equivalent to 259,129,600 Ordinary Shares of RedHill Biopharma, issuable upon the exercise of warrants. This represents approximately 3.19% of the company's class of securities. The warrants are subject to a 4.99% ownership blocker, which prevents the full exercise of the warrants if it would result in ownership exceeding this threshold. As a result, the actual number of Ordinary Shares beneficially owned by the reporting persons is less than the number reported. The filing also includes a certification that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
生物製藥公司RedHill Biopharma Ltd.是最近於2023年12月31日向美國證券交易委員會（SEC）提交的附表13G修正案的主題。該文件由根據1940年《投資顧問法》第203條註冊的投資顧問Empery Asset Management, LP及其管理成員瑞安·萊恩和馬丁·霍提交。文件顯示，Empery Asset Management, LP持有647,824股美國存托股票（ADS），相當於RedHill Biopharma的259,129,600股普通股，可在行使認股權證時發行。這約佔公司證券類別的3.19％。認股權證受4.99％的所有權封鎖，如果認股權證會導致所有權超過該門檻，則無法全面行使認股權證。因此，申報人實益擁有的普通股的實際數量少於報告的數量。該文件還包括一份證明，證明收購證券的目的不是爲了改變或影響發行人的控制權。
生物製藥公司RedHill Biopharma Ltd.是最近於2023年12月31日向美國證券交易委員會（SEC）提交的附表13G修正案的主題。該文件由根據1940年《投資顧問法》第203條註冊的投資顧問Empery Asset Management, LP及其管理成員瑞安·萊恩和馬丁·霍提交。文件顯示，Empery Asset Management, LP持有647,824股美國存托股票（ADS），相當於RedHill Biopharma的259,129,600股普通股，可在行使認股權證時發行。這約佔公司證券類別的3.19％。認股權證受4.99％的所有權封鎖，如果認股權證會導致所有權超過該門檻，則無法全面行使認股權證。因此，申報人實益擁有的普通股的實際數量少於報告的數量。該文件還包括一份證明，證明收購證券的目的不是爲了改變或影響發行人的控制權。
有用
沒用